The aMAP score improves discrimination of prognostic models in hepatocellular carcinoma after radiofrequency ablation - Scorecard - MDSpire

The aMAP score improves discrimination of prognostic models in hepatocellular carcinoma after radiofrequency ablation

  • By

  • Luchang Fan

  • Yiyan Zhang

  • Jianmin Ding

  • Yan Zhou

  • Jun Li

  • Qiong Wu

  • Shuqin Cheng

  • Fengmei Wang

  • Xiang Jing

  • June 17, 2026

  • 0 min

Share

Clinical Scorecard: Enhancing Prognostic Model Accuracy in Hepatocellular Carcinoma Post-Radiofrequency Ablation with the aMAP Score

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with newly diagnosed HCC undergoing RFA, BCLC stage 0 or A, Child-Pugh grade A or B
Care Setting

Key Highlights

  • exclusion_rate

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • I
      • n
      • c
      • l
      • u
      • d
      • e
      • s
      • p
      • e
      • c
      • i
      • f
      • i
      • c
      • f
      • o
      • l
      • l
      • o
      • w
      • -
      • u
      • p
      • i
      • n
      • t
      • e
      • r
      • v
      • a
      • l
      • s
      • f
      • o
      • r
      • m
      • o
      • n
      • i
      • t
      • o
      • r
      • i
      • n
      • g
      • r
      • e
      • c
      • u
      • r
      • r
      • e
      • n
      • c
      • e
      • .

      Risks

        Patient & Prescribing Data

        Add details on the calculation of the aMAP score.

        Clinical Best Practices

        • examples

        Related Resources & Content

        Original Source(s)

        The aMAP score improves discrimination of prognostic models in hepatocellular carcinoma after radiofrequency ablation

        • by Luchang Fan, Yiyan Zhang, Jianmin Ding, Yan Zhou, Jun Li, Qiong Wu, Shuqin Cheng, Fengmei Wang, Xiang Jing

        • June 17, 2026

        Related Content

        Spontaneous intracerebral hemorrhage associated with lenvatinib in advanced hepatocellular carcinoma without conventional risk factors: a case report literature review

        Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report

        Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression